Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate for Alcohol Use Disorder in Liver Transplant Recipients
NCT06471686Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in alcohol use disorder (AUD) comparing Acamprosate with Standard of Care (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 14 weeks and Incidence of Treatment-Emergent Liver Test Changes at 14 weeks. Started Dec 2021; status: completed.
02
Drugs
acamprosate
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06471686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471686.